UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 16, 2014
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its charter)
| Nevada | 45-5192997 |
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.) |
Commission File No. 333-191725
4700 Spring Street, St 304, La Mesa, California 91942
(Address of Principal Executive Offices)
(619) 702 1404
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement
On December 17, 2014 Dr. Christine Ichim assigned to Regen BioPharma, Inc. ( the “Company”) all right, title, and interest in and to the invention described in US Patent Application Serial No. 14/572,574 “TREATMENT OF MYELODYSPLASTIC SYNDROME BY INHIBITION OF NR2F6”
The foregoing description of the Assignment is not complete and is qualified in its entirety by reference to the text of the Assignment, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
Item 9.01 Exhibits.
| Exhibit No. | Description of Exhibit | |
| 10.1 | Assignment 12/17/2014 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Regen Biopharma, Inc. | |
| Dated: December 17, 2014 | By: /s/ David Koos |
| David Koos | |
| Chief Executive Officer |
Exhibit 10.1
ASSIGNMENT OF INVENTION AND PATENT APPLICATION
Whereas I, Christine Ichim, a citizen of the Canada residing in Spring Valley, CA herein referred to as ASSIGNOR, have invented new and useful innovations described in “TREATMENT OF MYELODYSPLASTIC SYNDROME BY INHIBITION OF NR2F6”, the specification of which was filed on December 16, 2014 as U.S. Non-Provisional Patent Application No 14/572,574, herein referred to as the Invention
And Whereas, Regen BioPharma, Inc., with its principal place of business at 4700 Spring St., Suite 304, La Mesa, CA 91942 herein referred to as ASSIGNEE, desires to acquire the entire right, title, and interest in and to the said Invention,
Now therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby acknowledges that they have sold, assigned, transferred, and set over, and by these presents do hereby sell, assign, and transfer, and set over unto ASSIGNEE and its successors and assigns, 100% of the following:
(A) ASSIGNOR’S right, title and interest in and to the Invention entitled in“TREATMENT OF MYELODYSPLASTIC SYNDROME BY INHIBITION OF NR2F6”, US Non- Provisional Patent Application No. 14/572,574 filed December 15, 2014,
(B) any patent or reissues that claim priority to U.S. Non-Provisional Application No 14/572,574; and
(C) any continuations, continuations-in-part, substitutes, or divisionals that claim priority to US Non-Provisional Application No. 14/572,574.
ASSIGNOR authorizes and requests the Commissioner for Patents to issue any resulting patent(s) as follows: 0% to ASSIGNOR and 100% to ASSIGNEE.
ASSIGNOR hereby further sells, assigns, transfers and sets over unto ASSIGNEE, 100% of ASSIGNOR’S entire right, title, and interest in and to said invention in the United States and every country foreign to the United States. ASSIGNOR agrees to execute all papers, give any required testimony, and perform other lawful acts, at ASSIGNEE’S expense, as ASSIGNEE may require to enable ASSIGNEE to perfect ASSIGNEE’S interest in any resulting patent of the United States and countries foreign thereto, and to acquire, hold, enforce, convey, and uphold the validity of said patent and reissues and extensions thereof, and ASSIGNEE’S interest therein.
In testimony whereof ASSIGNOR intending to be legally bound hereunto affix his signature.
ASSIGNOR
| /s/ Christine Ichim | December 17, 2014 |
| (Christine Ichim) | (Date) |